


Ro5-3335

Chemical Properties

CAS No. : 30195-30-3
 Formula: C₁₃H₁₀ClN₃O
 Molecular Weight: 259.69
 Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.



Biological Description

Description	Ro5-3335 (CBFβ-Runx1 inhibitor II) is core binding factor (CBF) inhibitor; preferentially kills human leukemia cell lines with CBF fusion proteins (IC ₅₀ = 1.1 μM). Ro5-3335 represses RUNX1/CBFβ-dependent transactivation in reporter assays and inhibits transcriptional regulation by RUNX1 and CBFβ. Ro5-3335 also reduces the leukemia burden in a mouse model. Attenuates RUNX1-dependent hematopoiesis in zebrafish embryos. It also is a Tat antagonist and inhibits HIV-1 replication in vitro.
Targets(IC ₅₀)	Others,DNA/RNA Synthesis

Solubility Information

Solubility	DMSO: 60 mg/mL (231.04 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (7.7 mM),Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	3.8507 mL	19.2537 mL	38.5075 mL
5 mM	0.7701 mL	3.8507 mL	7.7015 mL
10 mM	0.3851 mL	1.9254 mL	3.8507 mL
50 mM	0.077 mL	0.3851 mL	0.7701 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Cunningham L, et al. Identification of benzodiazepine Ro5-3335 as an inhibitor of CBF leukemia through quantitative high throughput screen against RUNX1-CBF β interaction. Proc Natl Acad Sci U S A. 2012 Sep 4;109(36):14592-7.

Lin W, Wan X, Sun A, et al. RUNX1/EGFR Pathway Contributes to STAT3 Activation and Tumor Growth Caused by Hyperactivated mTORC1. Molecular Therapy-Oncolytics. 2021

Wang Y, Wang Q, Wang B, et al. Inhibition of EZH2 ameliorates bacteria-induced liver injury by repressing RUNX1 in dendritic cells. Cell death & disease. 2020, 11(11): 1-13.

Cupelli LA, Hsu MC. The human immunodeficiency virus type 1 Tat antagonist, Ro 5-3335, predominantly inhibits transcription initiation from the viral promoter. J Virol. 1995 Apr;69(4):2640-3.

Okuda T, RUNX1/AML1: a central player in hematopoiesis. Int J Hematol. 2001 Oct;74(3):252-7.

Wu Y, Hu S S, Zhang R, et al. Single cell RNA sequencing unravels mechanisms underlying senescence-like phenotypes of Alveolar Macrophages. iScience. 2023

Cui X, Huo D, Wang Q, et al. RUNX1/NPM1/H3K4me3 complex contributes to extracellular matrix remodeling via enhancing FOSL2 transcriptional activation in glioblastoma. Cell Death & Disease. 2024, 15(1): 98.

Wang Y, Wang Q, Wang B, et al. Inhibition of EZH2 ameliorates bacteria-induced liver injury by repressing RUNX1 in dendritic cells[J]. Cell death & disease. 2020, 11(11): 1-13.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E_mail: info@targetmol.com Address: 34 Washington Street, Wellesley Hills, MA 02481